Stay updated on ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    7 days ago
    No Change Detected
  3. Check
    14 days ago
    Change Detected
    Summary
    The page appears to have no significant changes to core study information (eligibility, endpoints, locations, or status); only minor layout/UI adjustments are visible. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.5%
    Check dated 2025-10-27T21:03:51.000Z thumbnail image
  4. Check
    36 days ago
    Change Detected
    Summary
    Core content updated to include a government-funding operating status advisory and a new revision/version (v3.2.0); previous update label and old revision (v3.1.0) were removed.
    Difference
    4%
    Check dated 2025-10-06T08:12:57.000Z thumbnail image
  5. Check
    43 days ago
    Change Detected
    Summary
    The page has been updated with newer revision details (v3.1.0), dates, and policy notes (IPD plan), while older statuses and legacy dates (e.g., Active, not recruiting; 2024 dates) were removed. This signals an update to product information and governance without altering core content.
    Difference
    3%
    Check dated 2025-09-29T04:38:54.000Z thumbnail image
  6. Check
    57 days ago
    Change Detected
    Summary
    Updated page revision from v3.0.1 to v3.0.2 and removed the 'Back to Top' element. No other substantive content changes (pricing, stock, or time slot availability) are indicated.
    Difference
    0.3%
    Check dated 2025-09-14T21:57:41.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.
    Difference
    0.3%
    Check dated 2025-09-07T19:15:26.000Z thumbnail image
  8. Check
    72 days ago
    Change Detected
    Summary
    The web page has updated its facility name and location details, specifically adding 'Washington D.C., District of Columbia, United States, 20007' and 'Skin and Connective Tissue Diseases', while removing several related medical topics and previous location terms.
    Difference
    3%
    Check dated 2025-08-31T12:29:16.000Z thumbnail image

Stay in the know with updates to ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ARV-471 plus Everolimus in ER+, HER2- Breast Cancer Clinical Trial page.